Novartis

Tasigna Lawsuit News: Recent Studies Suggest Leukemia Drug May Increase Risk for Arteriosclerosis, Peripheral Artery Disease & Related Vascular Conditions

NEW YORK, NY — Tasigna lawsuits filed in recent months have highlighted a growing body of scientific evidence linking the leukemia drug to arteriosclerosis, peripheral artery disease, and related vascular conditions. For example, in 2011, the American Journal of Hematology published a study involving 24 patients who were taking Tasigna to treat chronic myelogenous leukemia … Continue reading Tasigna Lawsuit News: Recent Studies Suggest Leukemia Drug May Increase Risk for Arteriosclerosis, Peripheral Artery Disease & Related Vascular Conditions

GENEVA | Novartis general counsel resigns over deal with Trump lawyer

GENEVA — Novartis says its top lawyer is retiring over the Swiss pharmaceuticals company’s relationship with a firm owned by U.S. President Donald Trump’s personal lawyer, Michael Cohen. The Basel-based drugs company said general counsel Felix Ehrat was stepping down “in the context of discussions surrounding Novartis’ former agreement with Essential Consultants, owned by Michael … Continue reading GENEVA | Novartis general counsel resigns over deal with Trump lawyer

New, long-acting drugs cut frequency of migraine headaches

November 29, 2017 (AP)(STL.NEWS)–New, long-acting drugs may hold hope for millions of people who often suffer migraines. Studies of two of these medicines, given as shots every month or so, found they cut the frequency of the notoriously painful and disabling headaches. The drugs are the first preventive medicines developed specifically for migraines. They work … Continue reading New, long-acting drugs cut frequency of migraine headaches